Jie Ge
9 Papers
62 Citations
Jie Ge is an academic researcher. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Jie Ge,Emmanuel Normant,James R Porter,Janid A. Ali,Marlene S Dembski,Yun Gao,Asimina T. Georges,Louis Grenier,Roger H. Pak,Jon Patterson,Jens Sydor,Thomas T. Tibbitts,Jeffrey K. Tong,Julian Adams,Vito J. Palombella +14 more
TL;DR: The synthesis and evaluation of a highly soluble hydroquinone hydrochloride derivative of 17-AAG, 1a (IPI-504), and several of the physiological metabolites show comparable binding affinity to human Hsp90 and its endoplasmic reticulum (ER) homologue, the 94 kDa glucose regulated protein (Grp94).
204
Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy.
TL;DR: Key milestones in the development of the natural product class as anti-cancer drugs including discovery of the compounds and their anti-tumor effects, identification of Hsp90 as their biological target, the structure-activity relationships that have been identified in this interesting class of compounds, and development of clinical candidates for the treatment of cancer patients are surveyed.
68
Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo
Bonnie Tillotson,Kelly Slocum,John Coco,Nigel Whitebread,Brian Thomas,Kip A. West,John Macdougall,Jie Ge,Janid A. Ali,Vito J. Palombella,Emmanuel Normant,Julian Adams,Christian C. Fritz +12 more
TL;DR: A novel binding assay was evaluated both in vitro and in vivo and could be used as a pharmacodynamic readout in the clinic and indicate Hsp90 occupancy to be a better predictor of PD than either plasma PK or tumor PK.
44
Pharmaceutical development of IPI-504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer
James R. Porter,Julian Adams,Rebecca Ahn,Vince Ammoscato,Brendan Arsenault,Brian C. Austad,Gary Baker,Johan Sebastian Basuki,Marlene R. Booth,Matthew Campbell,Bennett Carter,Michael Curtis,Kris Depew,Mark Douglas,Jie Ge,Louis Grenier,Joseph Helble,John Henderson,Natalie Goltz,Dumitru Ionescu,Laila Kott,Jason Kropp,John Lee,Kaiming Li,Bradley Maurer,Denise Mayes,Roger H. Pak,Jason J. Piotrowski,Jennifer R. Porter,David Rusch,Geoff E. Sylvester,Steven G. Wong,James R. Wright +32 more
TL;DR: The development challenges associated with redox active molecules are significant due to the pH, oxygen, and temperature sensitivities associated with such chemotypes and the API and sterile drug product manufacturing processes thus warrant the monitoring and control of these key variables.
2
Genomic clonal evolution correlated with phenotype and prognosis in gastric cancer
Jie Ge,Xuanyang Li,Zhenghao Deng,Xuan Gao,Yaoyao Liu,Xingui Xiong,Xianhui Zhao,H. Peng,Xin Yi,Xue-ming Xia,Zihua Chen,Lifeng Li,Haiyan Zhou,Heli Liu +13 more
TL;DR: A prognostic-relevant subtype based on clone number is identified, indicating patients with high CN showed high tumour mutation burden and significantly enriched in Adherens junction, ERBB2 regulates cell motility, and signaling byWNTpathway, indicating CN may have potential risk of tumour metastasis and benefit from immunotherapy